Combination therapy with the MET inhibitor savolitinib and the EGFR inhibitor osimertinib showed robust and durable clinical responses among patients with EGFR-mutated and MET-amplified non-small-cell lung cancer (NSCLC), according to results of the phase Ib TATTON study presented at AACR 2019.
Gilteritinib, a novel inhibitor of the tyrosine kinase FLT3, improves survival outcomes among patients with relapsed or refractory acute myeloid leukaemia (AML) with FLT3 mutations vs standard chemotherapy, according to results of the phase III ADMIRAL trial reported at the American Association for Cancer Research (AACR) Annual Meeting 2019 held in Atlanta, Georgia, US.
Oral rucaparib as maintenance treatment showed encouraging clinical responses in patients with advanced BRCA1-, BRCA2-, or PALB2-mutated pancreatic cancer, according to an interim analysis presented at AACR 2019.
Patients with previously-treated non-small-cell lung cancer (NSCLC) who responded early to nivolumab at 6 months showed better long-term survival compared with responders to docetaxel, according to pooled analyses of CheckMate 017 and CheckMate 057 presented at the AACR 2019 Annual Meeting.
Pembrolizumab in combination with pemetrexed and platinum chemotherapy significantly improves overall survival (OS) and progression-free survival (PFS) vs chemotherapy alone in patients with untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) with liver or brain metastases, a post hoc analysis of the phase III KEYNOTE-189 trial has shown.
Patients with advanced small cell lung cancer (SCLC) who experience disease progression despite two or more lines of therapy could benefit from pembrolizumab in the third-line setting, according to results from the phase 1b KEYNOTE-028 and phase II KEYNOTE-158* studies presented at AACR 2019.
Patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) responded well to the novel next-generation Pl3K-delta inhibitor umbralisib, according to updated results of the UNITY-NHL* trial presented at AACR 2019.
Men with advanced prostate cancer who have pre-existing cardiovascular disease (CVD) may have an elevated mortality risk after treatment with abiraterone acetate compared with men who do not have CVD, according to a study presented at AACR 2019.
Tumour treating fields (TTFields), alternating electric fields delivered via transducer arrays placed on the scalp, have emerged as a new modality of treatment for glioblastoma (GBM), with studies showing improved survival in patients with newly diagnosed or recurrent disease. New data presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 held in Atlanta, Georgia, US, provide insights into its use in GBM treatment.